ATOS · Atossa Therapeutics, Inc. · Metrics
$1.65
-0.10 (-5.71%)
At close · Nov 20
Return incl. dividend (before tax)
Q2 2023 earnings call transcript
Going-concern doubt
— flagged Nov 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Substantial doubt exists about our ability to continue as a going concern.”View the 10-Q filed Nov 10, 2026
Market Cap
$15.92M
Shares
9.98M
Volume · Nov 20
48.93K
Avg daily vol (3M)
67.59K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
ATOS metrics
67 of 125 screener metrics currently available.
Market overview
2 metricsShare price
$1.60
Market cap
$15.92M
Price action
23 metricsPrice change (1W)
-9.8%
Price change (30D)
-30.8%
Price change (3M)
-32.4%
Price change (6M)
-64.8%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
$13.50
52-week low
$1.75
Change from 52-week high
-87.0%
Change from 52-week low
+0.0%
Annualized volatility
87.8%
Annualized volatility (3M)
75.2%
Implied volatility (30D)
74.0%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.5
RSI (14D)
31.0
Price vs SMA 50
-23.3%
Price vs SMA 200
-49.9%
Avg volume (3M)
67,925
Relative volume
0.4
Average dollar volume
$161,118
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
9.98M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.8
reciprocal yield 124.5%
FCF yield
-202.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-198.4%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2025-03-25
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
−$130,653
Operating profit (TTM)
−$35.90M
Net income (TTM)
−$34.66M
Trailing 12 months
Diluted EPS (TTM)
$-3.89
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+15.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-159.4%
Return on assets
-131.0%
Debt / equity
0.0
Current ratio
5.3
EBITDA (TTM)
—
Free cash flow (TTM)
−$35.29M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$20.57M
Latest balance sheet
Cash & equivalents
$20.57M
Total assets
$26.45M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$35.28M
Capital expenditures (TTM)
$7,000
R&D (TTM)
$19.21M
SG&A (TTM)
—
Stock compensation (TTM)
$2.59M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
35
13F filer change QoQ
+3
Institutional ownership
9.7%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
1.3%
Private-fund adviser ownership
1.3%
Active holders' share change QoQ
-63.4%
Holder tenure
10.4
Price vs estimated holder cost
-88.0%
Ownership (registered funds)
1 metricsIndex-fund ownership
4.7%
Short interest
3 metricsShort interest
5.3%
Latest settlement · 7.6 days to cover
Days to cover
7.6d
Short-squeeze score
48 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged
Key facts
CIK
1488039
CUSIP
04962H704
13F (30d)
61 filings
35 filers
Visit website
Investor relations